Clinical Trial: Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Rheumatoid Arthritis and Psoriatic Arthritis: A Single Site, Pragmatic Randomized Controlled Trial

U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07111494) titled 'Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Rheumatoid Arthritis and Psoriatic Arthritis: A Single Site, Pragmatic Randomized Controlled Trial' on Aug. 01.

Brief Summary: Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess the effectiveness of if GLP-1s, a medication used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.

The main objectives it aims to a...